Expedition Therapeutics develops treatments for COPD and other inflammatory respiratory diseases.
Expedition Therapeutics has raised $115.0M in total funding. The most recent round was Series B. The last funding was announced in August 2026.
Expedition Therapeutics's investors include General Atlantic, RA Capital Management, Balyasny Asset Management, Vivo Capital, Venrock.
Expedition Therapeutics is headquartered in San Francisco, United States.
Expedition Therapeutics develops treatments for COPD and other inflammatory respiratory diseases.
Expedition Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Expedition Therapeutics — Funding & Investors." VCBacked, August 5, 2026, https://www.vcbacked.co/company/expedition-therapeutics. Accessed October 30, 2026.
VCBacked. (2026). Expedition Therapeutics — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/expedition-therapeutics
{{cite web |title=Expedition Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/expedition-therapeutics |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated